Search | Clinical Trials Finder

Conditions: Huntington's Disease
Interventions: Pridopidine, Placebo; Drug · Other
Lead sponsor: Prilenia; Industry
Eligibility: 21 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more

Conditions: Arthritis, Rheumatoid
Interventions: GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 46
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more

Conditions: Marijuana Dependence
Interventions: Oxytocin, Saline; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: VX-407, Placebo, Midazolam; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
Interventions: methotrexate, methotrexate - etanercept - prednisolone arm; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 2 Years to 17 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 15
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 12 more

Conditions: Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions: Buprenorphine; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Pain, Opioid Use, Androgen Deficiency, Back Pain
Interventions: Testosterone Cypionate, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 60 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib, Placebo to match filgotinib, csDMARDs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 55
States / cities: Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more

Conditions: Keloid
Interventions: Botulinum toxin type A, Vehicle; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hypoactive Sexual Desire Disorder, Sexual Dysfunctions, Psychological
Interventions: Ginkgo Biloba, Sex Therapy (genital focus); Drug · Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Opioid Use Disorders
Interventions: CAM2038 SC injection, SL BPN/NX tabs, placebo SC injections, SL placebo tablets; Drug
Lead sponsor: Braeburn Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 36
States / cities: Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more

Conditions: HIV Infections
Interventions: Automated diary system; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 24 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Tampa, Florida • Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Amprenavir; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Memphis, Tennessee

Conditions: Antiviral Drug
Interventions: JST-018 combination of 3 monoclonal antibodies, Placebo; Biological · Drug
Lead sponsor: Just-Evotec Biologics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Plantar Fasciitis
Interventions: DAXI 80 U, DAXI 120 U, Placebo; Biological · Other
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more

Conditions: Healthy Volunteer
Interventions: Placebo, RO4917838, diazepam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 177 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Postoperative Pain
Interventions: Preoperative Gabapentin/Postoperative Placebo, Preoperative Gabapentin/Postoperative Gabapentin; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Atrophic Vaginitis
Interventions: Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 44
States / cities: Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more

Conditions: Single Ventricle Heart Disease
Interventions: Udenafil, Placebo; Drug
Lead sponsor: Mezzion Pharma Co. Ltd; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 26
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 22 more

Conditions: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions: Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 23
States / cities: Los Angeles, California • Monterey, California • Orange, California + 19 more

Conditions: Alcohol Withdrawal
Interventions: Prazosin, 12-Step Facilitation with Relapse Prevention and Contingency Management; Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Urea Cycle Disorders
Interventions: HPN-100, Buphenyl (NaPBA); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Long Beach, California • Los Angeles, California • Stanford, California + 18 more

Conditions: Topical Antisepsis
Interventions: Chlorhexidine gluconate, ChloraPrep One Step, Sterile saline; Drug
Lead sponsor: C. R. Bard; Industry
Eligibility: 16 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: COVID-19, SARS-CoV2
Interventions: SAB-185, Normal saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 3
States / cities: Wichita, Kansas • Syracuse, New York • San Antonio, Texas

Search by objective public record fields.

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

Effect of Oxytocin on Craving and Therapy Response

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

Microbicides Acceptability Among Sexually Active Young Women

Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors

Phase 1 Study on the Safety, Tolerability, and Pharmacokinetics of JST-018 in Healthy Adults

DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis

A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users

Effect of Perioperative Gabapentin on Postoperative Opioid Requirements

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

Fontan Udenafil Exercise Longitudinal Assessment Trial

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Prazosin for Alcohol Use Disorder With Withdrawal Symptoms

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

Preoperative Skin Preparation Evaluation

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants